<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468543</url>
  </required_header>
  <id_info>
    <org_study_id>QCL117924</org_study_id>
    <secondary_id>2017-000982-61</secondary_id>
    <nct_id>NCT03468543</nct_id>
  </id_info>
  <brief_title>Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects</brief_title>
  <official_title>A Study Designed to Determine the Gastro-Retentive and Modified Release Properties of Memantine Hydrochloride (HCl) Prototype Capsule Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lyndra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lyndra Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess how long modified release (MR) memantine hydrochloride prototype capsule
      formulations stay in the stomach as determined by magnetic resonance imaging (MRI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, single dose, 5-period study in 24 healthy male and
      female subjects, with an optional Period 6, if required. It is expected the study will be
      executed in 3 cohorts of 8 subjects, with each cohort participating in up to 2 study periods
      (total of up to 6 study periods). Cohort 3 may be conducted in parallel with Cohort 2.

      Subjects will be dosed in a sequential manner, as appropriate. Each subject will be
      administered up to 2 regimens (2 different prototype capsule formulations) across 2 study
      periods. There will be a minimum 35-day interval between each dose administration.

      Subjects will have an MRI scan performed on Days 2, 4, 7, 10 and 14 of each period to assess
      the gastric retentive properties of the formulation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Per protocol stopping rules
  </why_stopped>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Actual">September 18, 2017</completion_date>
  <primary_completion_date type="Actual">September 18, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric Retention by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>7 Days</time_frame>
    <description>Presence of formulation in stomach by MRI</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Gastric Retention</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride MR Prototype Capsule Formulation A</intervention_name>
    <description>Memantine HCl MR capsule formulation will be administered orally in a single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Memantine HCl Capsule Formulation A (50 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride MR Prototype Capsule Formulation B</intervention_name>
    <description>Memantine HCl MR capsule formulation will be administered orally in a single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Memantine HCl Capsule Formulation B (50 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride MR Prototype Capsule Formulation C</intervention_name>
    <description>Memantine HCl MR capsule formulation will be administered orally in a single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Memantine HCl Capsule Formulation C (50 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride MR Prototype Capsule Formulation D</intervention_name>
    <description>Memantine HCl MR capsule formulation will be administered orally in a single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Memantine HCl Capsule Formulation D (50 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride MR Prototype Capsule Formulation E</intervention_name>
    <description>Memantine HCl MR capsule formulation will be administered orally in a single dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Memantine HCl Capsule Formulation E (50 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>MRI will be performed on specified days according to protocol</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female subjects.

          2. Body mass index of 18.0 to 32.0 kg/m2.

          3. Subjects must demonstrate their ability to swallow a test capsule at screening.

          4. Must provide written informed consent.

        Exclusion Criteria:

          1. Subjects who have received any investigational medicinal product in a clinical
             research study within the previous 3 months.

          2. Subjects who have previously been enrolled in this study.

          3. History of any drug or alcohol abuse in the past 2 years.

          4. Current smokers and those who have smoked within the last 12 months.

          5. Individuals with clinically significant medical history relating to the
             gastrointestinal tract and potential for complications, thereof

          6. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results.

          7. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients.

          8. Individuals with contraindication to MRI imaging.

        Other protocol defined criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair, MBChB, DRCOG</last_name>
    <role>Study Director</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences (formerly Quotient Clinical)</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 19, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

